Date:6/28/2010

line portfolio 115 14.18 Astellas Pharma 115 14.18.1 Overview 115 14.18.2 IBS Pipeline Portfolio 115 15 Gastrointestinal Disorder Therapeutics Market: Pipeline Analysis 118 15.1 Preclinical 119 15.2 Phase I 120 15.3 Pipeline II 122 15.4 Phase III 126 15.5 Promising Drugs under Clinical Development for Crohn's Disease 129 15.5.1 Myoconda 129 15.5.2 Traficet-EN (CCX282) 129 15.5.3 MLN0002 (vedolizumab) 129 15.5.4 Orencia (abatacept) 129 15.5.5 ABT-874 129 15.5.6 Stelara 129 15.6 Promising Drugs under Clinical Development for Irritable Bowel Syndrome 130 15.6.1 Linaclotide (Linaclotide Acetate) 130 15.6.2 Asimadoline 130 15.6.3 Xifaxan (Rifaximin) 130 15.6.4 Bifantis (Bifidobacterium infantis 35624) 130 15.6.5 LX-103 131 15.6.6 YM060 (Ramosetron hydrochloride) 131 15.7 Promising Drugs under Clinical Development for GERD 131 15.7.1 XP19986 131 15.7.2 AZD3355 131 15.7.3 ADX10059 132 15.7.4 Vecam 132 15.8 Promising Drugs under Clinical Development for Ulcerative Colitis 132 15.8.1 Prograf (Tacrolimus) 132 15.8.2 Vedolizumab 132 15.8.3 Abatacept 132 15.8.4 Adalimumab 133 15.8.5 Golimumab 133 16 Global Gastrointestinal Disorder Therapeutics Market: Strategic Consolidations 134 16.1 Mergers and Acquisitions 134 16.1.1 Overview 134 16.1.2 GlaxoSmithKline Acquires AZ Tika Of AstraZeneca 134 16.1.3 ViroPharma Acquires Lev Pharmaceuticals 134 16.1.4 UCB Acquires Remaining Stake In Schwarz Pharma 134 16.1.5 Teva Pharmaceutical Acquires Bentley Pharmaceuticals 134 16.1.6 Gilead Sciences Acquires Nycomed Limited 135 16.2 Licensing Agreements 135 16.2.1 Overview 135 17 Global Gastrointestinal Disorder Therapeutics Market : Appendix 138 17.1 Market Definitions 138 17.2 Abbreviations 138 17.3 Research Methodology 139 17.3.1 Coverage 139 17.3.2 Secondary Research 139 17.3.3 Pri
'/>"/>

SOURCE MarketsandMarkets Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders